Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06171386

Microneedling vs Dermabrasion for Early Facial Scar Resurfacing

This study aims to determine whether microneedling or dermabrasion in the early post-operative period is superior in improving the appearance of surgical scars on the face.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Wake Forest University Health Sciences

Winston-Salem, North Carolina, 27157, United States

Location status: Recruiting

Location contact

Candace M Waters, MD

CONTACT

[email protected]

336-716-4000

About this study

Microneedling and dermabrasion are two common modalities that may be performed in-office to treat surgical scars.

Microneedling is a form of collagen induction therapy, often used in conjunction with platelet-rich plasma or hyaluronic acid.

Dermabrasion is a technique that improves the skin structure, quality, and appearance of scars through collagen remodeling and reepithelization.

To determine which modality is most effective, a prospective study; randomizing a volunteer sample of adult patients with new surgical vertical forehead scars will receive either dermabrasion or microneedling in the early postoperative period.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Volunteer adult patients will be identified by visiting the Facial Plastics and Reconstructive Surgery Clinic at Atrium Health Wake Forest Baptist.
  • Patients will be 18 years old+ and have a vertical surgical scar in the superior 1/3 of the face (trichion to glabella).
  • Patients will enroll in the clinic research registry and indicate an interest in being involved in the study.

Exclusion criteria

  • Patients who rate Types 4-6 on the Fitzpatrick scale will be excluded due to risk of poor outcome from dermabrasion.
  • There are no other planned exclusion criteria. Patients will not be excluded on the basis of gender, race/ethnicity, or age, provided that they meet the described inclusion criteria.

Treatment and study plan

Microneedling

Procedure

a form of collagen induction therapy

Dermabrasion

Procedure

a technique that improves the skin structure, quality, and appearance of scars through collagen remodeling and reepithelization

Primary outcomes

  1. Change in Vancouver Scar Scale Scores

    Time frame: Month 7

    Four characteristics of the scar are assessed. These are: vascularity, height, pliability, and pigmentation. Each characteristic is given a score, which are added together to give an overall score between 0 and 13 - lower scores denoting normal skin

  2. Change in Patient and Observer Scar Assessment Scale Scores

    Time frame: Month 7

    Items and total scale scores for the patient and observer: Each item on both scales has a score of 1 to 10. The lowest score is 1 and corresponds to the normal skin situation. The total score of both scales can be calculated simply by adding the scores of each of the six items. The total score will range from 6 to 60 - lower scores denoting normal skin

  3. Change in Global Aesthetic Improvement Scale Scores

    Time frame: Month 7

    5-point scale wherein 2 = much improved (marked improvement in appearance), 1 = improved (improvement in appearance but a touch-up or re-treatment is indicated - lower scores denoting normal skin

Secondary outcomes

  1. Patient perceived benefit

    Time frame: At time of procedure (pain scale); at 6 months (yes/no)

    At the time of intervention, patients will be asked to rank pain of procedure on a scale of 1-10 (1: minimal discomfort, 10: severe pain). At 6 months, they will also give a yes/no response as to whether they would undergo the study protocol (procedure) again.

Study contacts

Contact information is provided by the study sponsor or research team.

Alexa l Lacy

CONTACT

[email protected]

336-716-3850

Candace M Waters, MD

CONTACT

[email protected]

336-716-4000

Sponsors and collaborators

Lead sponsor

Wake Forest University Health Sciences

Other

Registry information

Important dates

Study start
2024
Primary completion
2027
Study completion
2027
First posted
Dec 14, 2023
Registry last updated
May 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.